InvestorsHub Logo
Followers 163
Posts 19648
Boards Moderated 2
Alias Born 12/09/2004

Re: indialong post# 183578

Sunday, 03/03/2019 5:00:46 PM

Sunday, March 03, 2019 5:00:46 PM

Post# of 459845
You raise an interesting question. The trial participants in the 2a were all getting 2-73 and continue to receive it as the trial was extended.

That suggests to me that none of them can be subjects in the new trial since they can not be assigned to the placebo group. Therefore they would be unblinded.

It is still unclear to me what dosages the remaining 2a subjects are receiving. I recall this has been discussed but no longer remember if the answer is known.

Anybody have that answer?

If investing was easy, everyone would be rich by now.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News